Related Experiment Video

Updated: May 9, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.4K

Patent spotlight on theranostics targeting fibroblast activation protein for personalized cancer care

Jason A Witek1, Allen F Brooks1, Benjamin L Viglianti1

  • 1Department of Radiology, University of Michigan, Ann Arbor, MI, USA.

Pharmaceutical Patent Analyst
|May 6, 2025
PubMed

Insights

Precision oncology is advancing with theranostics, combining imaging and treatment. This patent spotlight analyzes Fibroblast Activation Protein (FAP)-targeting radiopharmaceuticals, offering insights into this promising pan-cancer approach.

Area of Science:

  • Oncology
  • Radiopharmaceutical Therapy
  • Molecular Imaging

Background:

  • Theranostics merges diagnostic imaging and targeted therapy for improved cancer patient outcomes, particularly in late-stage disease.
  • Recent FDA approvals and commercialization have accelerated investment and development in theranostic agents.
  • Fibroblast Activation Protein (FAP) is a promising pan-cancer target due to its broad expression in various tumor types.

Purpose of the Study:

  • To provide the first comprehensive analysis of patents related to Fibroblast Activation Protein (FAP)-targeting radiopharmaceuticals.
  • To identify current trends, challenges, and future directions in the development of FAP-based theranostics.

Main Methods:

  • Systematic review and analysis of issued patents focusing on FAP-targeting radiopharmaceuticals.
  • Evaluation of patent scope, therapeutic applications, and diagnostic capabilities.

Main Results:

  • Identification of key innovators and trends in FAP-targeting radiopharmaceutical patenting.
  • Analysis of the therapeutic and diagnostic potential of patented FAP-targeting agents.
  • Overview of the intellectual property landscape surrounding FAP theranostics.

Conclusions:

  • FAP-targeting radiopharmaceuticals represent a significant area of innovation in precision oncology.
  • Patent analysis reveals a dynamic field with substantial academic and commercial interest.
  • Further development and strategic patenting are crucial for advancing FAP-based theranostics for broad cancer application.
Keywords:
FAPIPET imagingTheranosticsfibroblast activation proteinradiochemistryradiotherapy

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

591
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

4.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K